Fusion Pharmaceuticals to Present at the B. Riley Securities 2022 Virtual Oncology Conference

Rhea-AI Summary

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) announced its participation in the B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022, at 2:00 p.m. ET. CEO John Valliant, Ph.D., will present on behalf of the company. A webcast of the event will be available on the company's website, with a replay accessible for 90 days post-presentation. Fusion focuses on developing precision medicines through next-generation radiopharmaceuticals, with its lead program, FPI-1434, currently in Phase 1 clinical trials, and collaborations with AstraZeneca and Merck.

HAMILTON, ON and BOSTON, Jan. 21, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a fireside chat at the B. Riley Securities 2022 Virtual Oncology Conference on Thursday, January 27, 2022 at 2:00 p.m. ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

A webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.  

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear™ linker technology, Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), advancing to a Phase 1 study following the investigational new drug (IND) clearance; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion and Hamilton, Ontario-based McMaster University are building a current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company's growing pipeline of TATs.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-b-riley-securities-2022-virtual-oncology-conference-301465560.html

SOURCE Fusion Pharmaceuticals Inc.

FAQ

When is Fusion Pharmaceuticals presenting at the B. Riley Securities 2022 Virtual Oncology Conference?

Fusion Pharmaceuticals will present on January 27, 2022.

Who will represent Fusion Pharmaceuticals at the conference?

CEO John Valliant, Ph.D., will represent Fusion Pharmaceuticals.

Where can I watch the Fusion Pharmaceuticals conference presentation?

The presentation can be watched via the webcast available on Fusion's 'Events and Presentations' page.

What is Fusion Pharmaceuticals focused on?

Fusion Pharmaceuticals is focused on developing next-generation radiopharmaceuticals as precision medicines.

What is the lead program of Fusion Pharmaceuticals?

Fusion's lead program is FPI-1434, which is currently in Phase 1 clinical trials.

Does Fusion Pharmaceuticals have any collaborations with other companies?

Yes, Fusion has collaborations with AstraZeneca and Merck for developing targeted therapies.